Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab in EGPA (RITE)
NCT02947945Phase 2Unknown
- Sponsor
- National Jewish Health
- Start
- Sep 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of reslizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by National Jewish Health. Primary endpoint: Safety of reslizumab therapy at 12 months. Status: unknown.
02
Drugs
reslizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT02947945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947945.